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Original Article
Differing associations between Ab
accumulation, hypoperfusion, blood–brain
barrier dysfunction and loss of PDGFRB
pericyte marker in the precuneus and
parietal white matter in Alzheimer’s
disease
J Scott Miners, Isabel Schulz and Seth Love
Abstract
Recent studies implicate loss of pericytes in hypoperfusion and blood–brain barrier (BBB) leakage in Alzheimer’s disease
(AD). In this study, we have measured levels of the pericyte marker, platelet-derived growth factor receptor-b
(PDGFRB), and fibrinogen (to assess blood–brain barrier leakage), and analyzed their relationship to indicators of
microvessel density (von Willebrand factor level), ante-mortem oxygenation (myelin-associated glycoprotein:proteolipid
protein-1 ratio and vascular endothelial growth factor level), Ab level and plaque load, in precuneus and underlying white
matter from 49 AD to 37 control brains. There was reduction in PDGFRB and increased fibrinogen in the precuneus in
AD. These changes correlated with reduction in oxygenation and with plaque load. In the underlying white matter,
increased fibrinogen correlated with reduced oxygenation, but PDGFRB level was unchanged. The level of platelet-
derived growth factor-bb (PDGF-BB), important for pericyte maintenance, was increased in AD but mainly in the
insoluble tissue fraction, correlating with insoluble Ab level. Loss of the PDGFRB within the precuneus in AD is
associated with fibrinogen leakage and reduced oxygenation, and related to fibrillar Ab accumulation. In contrast,
fibrinogen leakage and reduced oxygenation of underlying white matter occur independently of loss of PDGFRB, perhaps
secondary to reduced transcortical perfusion.
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Introduction
Histological and ultrastructural examination of human
post-mortem brain tissue has shown evidence of peri-
cyte degeneration in AD,1–4 and blood–brain barrier
(BBB) breakdown, indicated by the extravasation of
serum proteins such as ﬁbrinogen, has also been
widely reported.3–7 Pericyte loss and BBB breakdown
were found to be associated with higher Ab level and to
be exacerbated in APOE e4 carriers.3,4 In the present
study, we have used biochemical methods to investigate
the relationships between the pericyte marker
PDGFRB,4,8,9 ﬁbrinogen, cerebral hypoperfusion,
APOE genotype, Braak tangle stage, and the pericyte
trophic protein PDGF-BB, by analysis of the precuneus
and underlying white matter from post-mortem brain
tissue in AD and control brains.
Cerebral blood ﬂow declines within the medial par-
ietal cortex (precuneus) early in the development of
Alzheimer’s disease (AD). This is the ﬁrst aﬀected
region of brain to show hypoperfusion in AD, up to
10 years before clinical symptoms.10–16 Reduced
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cerebral blood ﬂow predicts the onset of dementia in
AD17 and occurs well before behavioral or pathological
alterations in animal models.18–20 It causes ischemic
damage and may exacerbate AD pathology by increas-
ing the production and reducing the clearance of Ab
(reviewed in Chui et al.21). Conversely, there is evidence
that the accumulation of Ab reduces cerebral blood
ﬂow not only through the development of cerebral
amyloid angiopathy (CAA) but also by inducing both
chronic vasoconstriction and interfering with autoregu-
lation and neurovascular coupling (reviewed in Love
and Miners22 and Miners et al.23).
We previously reported that chronic reduction in
oxygenation of brain tissue could be quantiﬁed by
comparison of the levels of two myelin proteins:
myelin-associated glycoprotein (MAG), which is
highly susceptible to reduced tissue oxygenation, and
proteolipid protein-1 (PLP-1), which is relatively resist-
ant.24–27 Both proteins are stable under post-mortem
conditions and, as they have half-lives of several
months, a decline in MAG:PLP1 reﬂects reduced oxy-
genation of oligodendrocytes over a sustained period
prior to death (reviewed in Love and Miners22,28).
Reduced oxygenation of the precuneus is evident at
an early stage of AD (i.e. Braak tangle stage III-IV
disease),26 and correlates strongly with the level of
endothelin-1 (EDN1), a potent vasoconstrictor, which
is increased in AD,26,27,29 probably as a consequence of
Ab42-mediated upregulation of endothelin-converting
enzyme-2 (ECE-2),30 but Ab40-mediated upregulation
of ECE-1 may also contribute.29
Several animal models have provided mechanistic
insights into the relationship between neurovascular
dysfunction and AD. Deletion of the Meox2 gene in
mice resulted in a perfusion deﬁcit that was associated
with increased Ab level (due to impeded LRP-1-
mediated clearance).31 Mice deﬁcient in platelet-derived
growth factor receptor-b (Pdgfrbþ/), a speciﬁc marker
of pericytes,32 showed age-related loss of pericytes,
associated with BBB breakdown, impaired neurovascu-
lar coupling, reduced capillary density and reduced
cerebral blood ﬂow.9 Accelerated progression of AD-
related pathology and neuronal loss was observed when
Pdgfrbþ/ mice were crossed with APPsw/0 transgenic
mice.33 BBB breakdown and impaired interstitial drain-
age of Ab were thought to be responsible for the accel-
erated neurodegeneration, as neuronal damage was
more marked in these mice than in those with a perfu-
sion deﬁcit alone.
Imaging studies have provided additional evidence
linking pericyte loss, BBB breakdown and cerebral
hypoperfusion in the early stages of AD. In 21 patients
with no cognitive impairment, 21 with mild cognitive
impairment and 19 patients with multiple sclerosis,
imaging revealed that BBB leakage within the
hippocampus was a feature of normal aging but was
exacerbated in the MCI group.34 The severity of BBB
leakage correlated with the CSF level of soluble
PDGFRB, a marker of pericyte injury.35 Van de
Haar et al.36,37 examined a small cohort of patients
with early AD and age-matched controls and found
that BBB leakage in early AD was associated with
cognitive decline and reduced cerebral blood ﬂow.
The precise interrelationship between these neurovascu-
lar abnormalities in early AD remains unclear. In clin-
ical and experimental studies of acute stroke,
hypoperfusion is closely followed by disruption of the
BBB.38,39 However, as noted above,9 pericyte loss can
itself lead to both BBB leakage and hypoperfusion.
In the present study, we have analyzed the relation-
ship between pericyte loss, BBB leakage and hypoper-
fusion in both the precuneus, as it is a region of early
and consistent vascular dysfunction in AD, and the
underlying white matter, which is perfused by perforat-
ing arterioles that pass through the precuneus. Present
ﬁndings reveal a strong association between Ab plaque
load, loss of pericyte protein PDGFRB, elevated
ﬁbrinogen and hypoperfusion in the cortex in AD.
However, in the underlying white matter there is
ﬁbrinogen accumulation and hypoperfusion in the
absence of loss of PDGFRB. Our ﬁndings suggest
that ﬁbrillar Ab accumulation plays a key role in peri-
cyte degeneration in human brain tissue and highlight
important diﬀerences between cerebral cortex and
white matter in the pathophysiology of neurovascular
dysfunction in early AD.
Materials and methods
Case selection
Brain tissue was obtained from the South West
Dementia Brain Bank, University of Bristol, UK,
with ethical approval from NRES committee South
West-Central Bristol, UK (NRES approval 08/H0106/
28þ 5). The brains had been dissected within 72 h of
death. The right cerebral cortex had been ﬁxed in buf-
fered formalin for three weeks before the tissue was
processed and paraﬃn blocks were taken for patho-
logical assessment. The left cerebral hemisphere had
been sliced and frozen at 80 C. We studied 49
brains from patients with AD (ages, mean 77.5 y, SD
8.2 y) with post-mortem delays of 4 to 72 h (mean
31.4 h, SD 19.3 h) and 37 control brains (ages 58 to
94 y (mean 79.8 y, SD 8.9 y) with post-mortem delays
from 3 to 67 h (mean 32.7 h, SD 16.3 h). All of the
brains had been subjected to detailed neuropathological
assessment. In those from patients with AD, the
diagnosis had been made according to the NIA-AA
guidelines.40 Control brains were from people with no
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history of dementia, few or absent neuritic plaques, a
Braak tangle stage of III or less and no other neuro-
pathological abnormalities. The demographic data,
neuropathological ﬁndings, and MRC identiﬁer num-
bers in this cohort are summarized in Supplementary
Tables 1 and 2.
The cohort overlapped that of a previous study of
several determinants of perfusion of the precuneus26
and parietal white matter24 in AD, vascular dementia,
and control brains. Measurements of MAG:PLP1,24,26
VEGF,27 and soluble and insoluble Ab40 and Ab4241
were previously reported. Ab plaque load had beenmea-
sured by determining the area fraction of cerebral cortex
immunopositive for Ab. Small vessel disease (SVD) had
been scored on a 4-point semi-quantitative scale as
previously described,25 according to the extent of
thickening of the arteriolar walls and associated narrow-
ing of the vessel lumina: 0¼ normal vessel wall thick-
ness, 1¼ slightly increased thickness, 2¼moderately
increased thickness, and 3¼markedly increased thick-
ness such that for many arterioles the diameter of the
lumen was <50% of the outer diameter of the blood
vessel. CAA had also been previously graded semi-
quantitatively on a 4-point scale by a method adapted
from that of Chalmers et al.42 and Olichney et al.,43 ran-
ging from ‘‘0’’ for vessels devoid of amyloid to ‘‘3’’ for
extensive vascular deposition.
Preparation of brain tissue
Frozen tissue was dissected from the left medial parietal
cortex (Brodmann area 7) and separate samples were
dissected from the underlying parietal white matter.
Biochemical analyses were performed on 200mg sam-
ples of the dissected tissue that were homogenized in a
Precellys homogenizer (Stretton Scientiﬁc, Derbyshire,
UK) and extracted in 1% sodium dodecyl sulfate lysis
buﬀer or guanidine-HCl, as previously described24,26,27
and then aliquoted and stored at 80C until required.
All measurements were made in duplicate and the mean
determined.
Measurement of PDGFRB
PDGFRB level was measured by sandwich ELISA
(duoset, Cat no DYC385, R&D systems, Oxford,
UK). High-binding capacity clear 96-well plates
(Costar EIA plates, R&D systems, Oxford, UK) were
coated overnight at room temperature with anti-human
PDGFRB capture antibody (diluted to 6 mg/ml in PBS).
The plate was washed ﬁve-times in PBS:0.05% tween-
20 and blocked for 2 h in PBS:1% bovine serum albu-
min (Sigma Aldrich, Dorset, UK) at room temperature.
Following a further wash step, brain tissue samples at
(2 llþ 98 ll PBS) or recombinant human PDGFR-b
(16,000  250 pg/ml) were incubated for 2 h at room
temperature without shaking. The plate was washed
and biotinylated anti-human PDGFRB detection anti-
body (diluted to 0.5 ug/ml in PBS) was added for 2 h at
room temperature without shaking. The plate was
washed and incubated for 20min at room temperature
with streptavidin:HRP (diluted 1 in 200 in PBS) (R&D
systems, UK) and then washed and incubated in the
dark with 3,30,5,50-tetramethylbenzidine (TMB) sub-
strate (R&D systems, UK) for 15min. Absorbance
was read at 450 nM following the addition of 2N sul-
furic acid, in a FLUOstar OPTIMA plate reader (BMG
labtech, Aylesbury, UK). The absolute concentration
of PDGFRB was interpolated from the standard
curve for each case, derived from duplicate measure-
ment of the recombinant PDGFRB.
To conﬁrm the speciﬁcity of the assay, we performed
immunoﬂuorescent labeling of sections of parietal
cortex and white matter with the PDGFRB detection
antibody used in the ELISA, in combination with anti-
body to smooth muscle actin or Von Willebrand factor
(vWF) (see supplementary information for methodo-
logical details). This conﬁrmed the ﬁnding of Craggs
et al.44 that PDGFRB is largely restricted to cells asso-
ciated with capillaries (Supplementary Figure 1). There
was negligible overlap of PDGFRB immunoﬂuorescent
signal with that of smooth muscle actin in the tunica
media of adjacent arterioles, and limited overlap of the
PDGFRB signal with that of vWF in the underlying
endothelium.
Measurement of fibrinogen
Fibrinogen content was measured in brain tissue hom-
ogenates by use of a commercially available sandwich
ELISA (Human Fibrinogen ELISA kit, Cat no
EH3057, Wuhan Fine Biological Technology Co,
Wuhan City, Hubei Province, China). The plate was
pre-coated with an anti-human ﬁbrinogen capture anti-
body. Recombinant human ﬁbrinogen or brain tissue
homogenate (50llþ 50 ll proprietary dilution buﬀer)
was incubated at 37C for 90min. The plate was
washed ﬁve times in PBS:0.05% tween-20 and biotiny-
lated-detection antibody added at 37C for 60min.
Bound antibody was detected as above (see
Measurement of PDGFRB). The absolute concentra-
tion of ﬁbrinogen was interpolated from measure-
ments of serially diluted recombinant human
ﬁbrinogen (600–9.375 ng/ml).
Measurement of hemoglobin
A colorimetric assay kit (Caymen Chemicals, Cat No
700540) (Ann Arbor, MI, USA) was used according
to the manufacturer’s instructions to measure
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the hemoglobin level in the brain tissue homogenates.
The proprietary hemoglobin detection reagent was
incubated with tissue homogenates and absorbance
measured at 560–590 nM in a FLUOstar OPTIMA
plate reader. Hemoglobin content was determined by
interpolation from measurements of serial dilutions of
hemoglobin (0.4–0.016 g/dl) and calculated using the
following equation
Hemoglobin g=dlð Þ ¼ corrected sample absorbanceð
 y interceptð Þ=slopeÞÞ
 10 sample dilution:
Measurement of vWF
vWF level in brain tissue homogenates was determined
by dot blot as previously described.24,27 Samples were
diluted in tris-buﬀered saline (TBS) (1 in 800)
and blotted onto nitrocellulose membrane (GE
Healthcare, St. Giles, UK) for 1 h at room temperature.
The membrane was blocked in 5% non-fat dried milk
protein (NFDMP) in TBS at 4C overnight, washed,
and then incubated for 1 h with polyclonal rabbit anti-
human VWF, (0.3 mg/ml) (Dako, Glostrup, Denmark)
at room temperature with agitation. The membrane
was washed then incubated with anti-rabbit peroxi-
dase-conjugated secondary antibody (Vector
Laboratories, Burlingame, CA, USA) in 5% NFDMP
diluted in 0.3% TBS-T for 1 h at room temperature
with agitation. The membrane was again washed and
then developed using chemiluminescent ECL substrate
(Millipore, Billerica, MA, USA) according to the
manufacturer’s guidelines. Image-J was used to meas-
ure the integrated density of each blot. Serial dilutions
of a standard reference brain tissue homogenate were
used to control for any blot-to-blot variation. We pre-
viously demonstrated that vWF is stable under condi-
tions of simulated post-mortem delay for up to 72 h at
4C or RT and that vWF level, measured by dot blot, is
an excellent indicator of microvessel density.24,45
Measurement of PDGF-BB
PDGFBB level in 1% sodium dodecyl sulfate lysis
buﬀer or guanidine-HCl extracts of the homogenized
brain tissue was measured by sandwich ELISA
(duoset, Cat no DY220, R&D systems, Oxford, UK).
High-binding capacity clear 96-well plates (Costar EIA
plates, R&D systems, Oxford, UK) were coated over-
night at room temperature with anti-human PDGF-BB
capture antibody (diluted to 0.4mg/ml in PBS). The
plate was washed ﬁve-times in PBS:0.05% tween-20
and blocked for 2 h in PBS:1% bovine serum albumin
(Sigma Aldrich, Dorset, UK) at room temperature.
Following a further wash step, brain tissue samples at
(5 llþ 95 ll PBS) or recombinant human PDGFRB
(2000 – 31.25 pg/ml) were incubated for 2 h at room
temperature without shaking. The plate was washed
and biotinylated anti-human PDGF-BB detection anti-
body (diluted to 0.4 lg/ml in PBS) was added for 2 h at
room temperature without shaking. The plate was
washed and incubated for 20min at room temperature
with streptavidin:HRP (diluted 1:200 in PBS) (R&D
systems, UK) and then washed and incubated in the
dark with 3,30,5,50-TMB substrate (R&D systems,
UK) for 15min. Absorbance was read at 450 nM fol-
lowing the addition of 2N sulfuric acid, in a FLUOstar
OPTIMA plate reader (BMG labtech, Aylesbury, UK).
The absolute concentration of PDGF-BB was interpo-
lated from the standard curve for each case, derived
from duplicate measurement of the recombinant
PDGF-BB.
Figure 1. Platelet-derived growth factor receptor-b (PDGFRB)
loss and blood–brain barrier (BBB) breakdown in the precuneus
in AD. (a) Bar chart showing reduced PDGFRB in AD compared
to age-matched controls. (b) Bar chart showing increased
fibrinogen level in AD compared to age-matched controls.
(c) Scatterplot showing a trend toward a negative correlation
between PDGFRB and fibrinogen level in the precuneus
(r¼0.25, P¼ 0.054). Each point in the scatterplot indicates a
single AD (red circle) or control (blue square) brain. The best-fit
linear regression line and 95% confidence interval are superim-
posed. (d) The level of von Willebrand factor (vWF) in the
precuneus did not differ significantly between AD and control
brains. The bars indicate the mean and SEM. **P< 0.001,
***P< 0.0001.
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Statistical analysis
Unpaired two-tailed t-tests or ANOVA with
Bonferroni post-hoc analysis were used for compari-
sons between groups, and Pearson’s or Spearman’s
test to assess linear or rank order correlation, as appro-
priate, with the help of SPSS version 16 (SPSS,
Chicago) and GraphPad Prism version 6 (GraphPad
Software, La Jolla, CA). P-values< 0.05 were con-
sidered statistically signiﬁcant. We also used Wizard
version 1.8.22 (http://www.wizardmac.com/) to per-
form multivariable regression analysis of the asso-
ciation of PDGFRB, ﬁbrinogen, and PDGF-BB with
age, gender, post-mortem delay, and diagnosis of AD.
Results
PDGFRB loss, BBB breakdown and reduced
microvessel density in the precuneus in AD
PDGFRB level was signiﬁcantly reduced in the precu-
neus in AD compared to age-matched controls
(P¼ 0.0002) (Figure 1(a)), and ﬁbrinogen level, which
rises with BBB breakdown3,4,6 was signiﬁcantly elevated
(P¼ 0.0026) (Figure 1(b)). Fibrinogen level tended to
vary inversely with PDGFRB level (r¼0.25,
P¼ 0.054) (Figure 1(c)), suggesting that BBB breakdown
was related to lower pericyte content within the precu-
neus. There was a small, non-signiﬁcant reduction in the
level of vWF in the precuneus in AD (Figure 1(d)).
We previously showed that vWF level is reduced in
mid-frontal cortex in AD but was unchanged or elevated
in regions of cerebrum that have less Ab pathology, such
as the thalamus.27
When grouped according to Braak tangle stage,
PDGFRB level was signiﬁcantly lower (Figure 2(a))
and ﬁbrinogen level higher (Figure 2(d)) in Braak
tangle stage V–VI (end-stage) disease than in Braak
stage 0–II brains (P< 0.01 for both). The diﬀerences in
PDGFRB level and ﬁbrinogen between Braak stage 0–II
and III–IV, and between Braak stage III–IV and V–VI
were not statistically signiﬁcant. PDGFRB level was sig-
niﬁcantly lower in APOE e3.4 (P< 0.01) and APOE e4.4
Figure 2. Platelet-derived growth factor receptor-b (PDGFRB) loss and blood–brain barrier (BBB) breakdown in relation to disease
severity (i.e. Braak tangle stage), APOE genotype, and cerebral amyloid angiopathy (CAA) in the precuneus in AD. Bar charts showing
(a) reduced PDGFRB in Braak tangle stage V–VI (end-stage) compared to Braak tangle stage 0–II. (P< 0.01) (b) reduced PDGFRB level
in APOE e3.4 (P< 0.01) and APOE e4.4 (P< 0.05) compared with APOE e2.3 individuals and (c) reduced PDGFRB level in severe CAA
compared to absent CAA (P< 0.01). Bar charts showing (d) increased fibrinogen level in Braak tangle stage V–VI (end stage) compared
to Braak stage 0–II (P< 0.01), (e) no significant difference in fibrinogen level in relation to APOE genotype and (f) increased fibrinogen
level in moderate CAA compared to absent CAA (P< 0.01). The bars indicate the mean and SEM. CAA severity scores adapted from
Olichney et al.:42,43 0¼ absent, 1¼mild, 2¼moderate, 3¼ severe.
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(P< 0.05) brains than in those with an APOE e2:3 geno-
type (Figure 2(b)) but did not vary between APOE e2.3
and e3.3. PDGFRB level was signiﬁcantly lower in
severe CAA than in brains without CAA (P< 0.01)
(Figure 2(c)). Fibrinogen level did not vary signiﬁcantly
with APOE genotype (Figure 2(e)) but was increased in
moderate CAA (P< 0.01) (Figure 2(f)).
Finally, to ensure that alterations in ﬁbrinogen level
within the brain were not caused by diﬀerences in blood
content, we compared ﬁbrinogen level after adjusting
the values (i) for hemoglobin content, and (ii) for
microvessel content/vWF level. The hemoglobin-
adjusted values remained higher in AD but the diﬀer-
ence did not quite reach signiﬁcance (P¼ 0.09)
(Supplementary Figure 2(a)). The vWF-adjusted
ﬁbrinogen values were also elevated in AD but again
did not reach statistical signiﬁcance (Supplementary
Figure 2(b)).
There was no signiﬁcant association between
PDGFRB in the precuneus, and gender, age or post-
mortem delay in either the AD or control cohort, or
when all cases were combined. Fibrinogen in the precu-
neus did not vary with gender or age but did increase
slightly with post-mortem delay in the AD (P¼ 0.018,
coeﬃcient of correlation 0.163) and combined cohorts
(P¼ 0.010, coeﬃcient of correlation 0.148). However,
the association of PDGFRB with AD remained signiﬁ-
cant (P¼ 0.004) after incorporating post-mortem delay
into a multivariable regression model (results not shown).
PDGFRB loss and fibrinogen accumulation in AD,
associated with cerebral hypoperfusion of the
precuneus
We previously reported that MAG:PLP1 was reduced
in the precuneus from an early stage of AD, indicating
Figure 3. Platelet-derived growth factor receptor-b (PDGFRB) loss and blood–brain barrier breakdown are associated with
hypoperfusion of the precuneus. (a) Scatterplot showing a strong positive correlation between PDGFRB and MAG:PLP1 (r¼ 0.24,
P¼ 0.006), i.e. the lowest PDGFRB levels were in samples with least preservation of MAG relative to PLP1. (b) Scatterplot showing a
negative correlation between PDGFRB level and VEGF level in the precuneus (r¼0.26, P¼ 0.029), i.e. the lowest PDGFRB levels
were in samples with greatest elevation in VEGF. (c) Scatterplot showing a negative correlation between fibrinogen level and
MAG:PLP1 (r¼0.30, P¼ 0.022) and (d) Scatterplot showing a strongly positive correlation between fibrinogen and VEGF level
(r¼ 0.49, P< 0.0001). Each point in the scatterplots indicates a single AD (red circle) or control (blue square) brain. The best-fit linear
regression lines and 95% confidence intervals are superimposed.
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a perfusion deﬁcit with respect to the energy require-
ments.26 In the present study, PDGFRB level corre-
lated positively with MAG:PLP1 (r¼þ0.34,
P¼ 0.006) and negatively with VEGF level (r¼0.26,
P¼ 0.029), providing evidence that pericyte loss is asso-
ciated with cerebral hypoperfusion (Figure 3(a) and (b)).
Fibrinogen level correlated negatively with MAG:PLP
(r¼0.30, P¼ 0.022) (Figure 3(c)) and positively with
VEGF (r¼ 0.49, P< 0.0001) (Figure 3(d)) indicating
that BBB breakdown is also associated with chronic
cerebral hypoperfusion.
PDGFRB loss and BBB breakdown, associated
with accumulation of parenchymal Ab within
the precuneus
PDGFRB level correlated negatively with parenchymal
Ab plaque load (r¼0.36, P¼ 0.010) (Figure 4(a)).
PDGFRB level also declined with increasing insoluble
Ab42 but this relationship did not reach statistical
signiﬁcance (r¼0.20, P¼ 0.097) (Figure 4(b)).
Fibrinogen level correlated positively with parenchymal
Ab load (r¼ 0.37, P¼ 0.015) (Figure 4(c)) and insoluble
Ab40 (r¼ 0.33, P¼ 0.006) (Figure 4(d)) but not Ab42.
No correlations were observed between either
PDGFRB or ﬁbrinogen with soluble species of Ab40
or Ab42.
Hypoperfusion of cerebral white matter in AD,
associated with fibrinogen accumulation without
reduction in PDGFRB
In contrast to the precuneus, the white matter did
not show signiﬁcant alteration in PDGFRB in AD
(Figure 5(a)). Fibrinogen level in the white matter was
signiﬁcantly higher in AD than controls (P¼ 0.05)
(Figure 5(b)) and remained higher after adjustment
for hemoglobin but not vWF level (Supplementary
Figure 2(c) and (d)). Unlike in the precuneus, in under-
lying white matter, PDGFRB correlated positively
(rather than negatively) with ﬁbrinogen level (r¼ 0.36,
P< 0.0001) (Figure 5(c)). Diﬀerences between AD and
Figure 4. Platelet-derived growth factor receptor-b (PDGFRB) loss and BBB breakdown in the precuneus in AD are related to Ab
level. (a–b) Scatterplots showing negative correlation between PDGFRB and Ab plaque load (area fraction of cortex immunopositive
for Ab) (r¼0.36, P¼ 0.022) and insoluble Ab42 level (r¼0.26, P¼ 0.029). (c–d) Scatterplots showing positive correlation
between fibrinogen level and Ab plaque load (r¼ 0.37, P¼ 0.015) and insoluble Ab40 (r¼ 0.35, P¼ 0.006). Each point in the
scatterplots indicates a single AD (red circle) or control (blue square) brain. The best-fit linear regression lines and 95% confidence
intervals are superimposed.
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control brains in vWF level in the parietal white matter
were not signiﬁcant (Figure 5(d)). White matter
PDGFRB and ﬁbrinogen level did not vary signiﬁ-
cantly with Braak tangle stage or APOE genotype
(Supplementary Figure 3).
We previously reported on chronic hypoperfusion
(reduction in MAG:PLP1) in the parietal white
matter in AD.24 Unlike in the precuneus, PDGFRB
level in the white matter correlated negatively with
MAG:PLP1 (r¼0.31, P¼ 0.004) (Figure 6(a))
and positively with VEGF (r¼ 0.19, P¼ 0.019)
(Figure 6(b)) indicating an increase in PDGFRB with
declining white matter perfusion. Fibrinogen level,
however, showed a strong negative correlation with
MAG:PLP1 (r¼0.48, P< 0.0001) and a strong
positive correlation with VEGF (r¼ 0.42, P< 0.0001),
suggesting a close relationship between breakdown of
the BBB and chronic hypoperfusion in the white matter
(Figure 6(c) and (d)).
There was no signiﬁcant association between
PDGFRB and ﬁbrinogen in the white matter, and
gender, age or post-mortem delay in either the AD or
control cohort, or when all cases were combined.
Increased PDGF-BB in AD, associated with
hypoperfusion, BBB leakiness, and Ab accumulation
To determine whether the PDGFRB loss in the precu-
neus was secondary to a decline in PDGF-BB (a key
trophic factor for pericytes), we measured the concen-
tration of PDGF-BB in the precuneus and underlying
white matter, in both SDS-extracted (soluble) and gua-
nidine-HCl (insoluble) fractions. In AD, the level of
PDGF-BB was signiﬁcantly increased in both regions
and in both fractions (P< 0.0001 for all comparisons
between AD and control brains except in the insoluble
white matter fraction where P¼ 0.001) (Figure 7). Of
possible relevance, the concentration of PDGF-BB was
approximately 3- to 4-fold higher in the insoluble than
the corresponding soluble fractions. In the precuneus,
PDGF-BB concentration showed highly signiﬁcant
positive correlations with the levels of insoluble Ab40
(r¼ 0.43, P< 0.01) and Ab42 (r¼ 0.40, P< 0.01)
(Supplementary Table 3). In contrast, PDGF-BB
showed weaker negative correlations with Ab40
(r¼0.298, P< 0.05) and Ab42 (r¼0.212, P< 0.05)
within the GuHCl-extract in the underlying white
matter, which contains much less insoluble Ab.41
There was no signiﬁcant association between PDGF-
BB in the precuneus or white matter, and gender, age or
post-mortem delay in either the AD or control cohort,
or when all cases were combined.
Discussion
We previously reported that oxygenation of both the
precuneus and the underlying white matter was reduced
in the early stages of AD.26 Present ﬁndings show the
reduced oxygenation of the precuneus to be associated
with loss of the pericyte protein PDGFRB, and the
accumulation of ﬁbrinogen and Ab (particularly
plaque-associated ﬁbrillar Ab). In contrast, hypoperfu-
sion of the underlying white matter (where the amount
of Ab is orders of magnitude lower than in the precu-
neus in AD41) was associated with ﬁbrinogen accumu-
lation in the absence of any reduction in PDGFRB.
The pathophysiological processes that underlie pericyte
degeneration, BBB breakdown, and cerebral hypoper-
fusion are thus region-speciﬁc and likely to be inﬂu-
enced by Ab level. In neither cortex nor white matter
Figure 5. Blood–brain barrier (BBB) breakdown in parietal
white matter in AD not associated with pericyte loss. (a) There
was no significant change in platelet-derived growth factor
receptor-b (PDGFRB) in the parietal white matter in AD. (b) Bar
chart showing increased fibrinogen level in white matter in AD
compared to age-matched controls. (c) Scatterplot showing
highly significant positive correlation between PDGFRB and
fibrinogen level in white matter (r¼ 0.36, P< 0.0001). Each point
indicates a single AD (red circle) or control (blue square) brain.
The best-fit linear regression line and 95% confidence interval are
superimposed. (d) The level of von Willebrand factor (vWF), a
marker of vessel density, was not significantly altered in the
parietal white matter in AD. The bars indicate the mean and SEM.
*P< 0.05.
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could loss of PDGFRB be attributed to a reduced level
of PDGF-BB, which was elevated in AD. However, as
discussed below, the diﬀerential distribution of ﬁbrillar
Ab may have inﬂuenced the availability of this trophic
factor.
Our ﬁndings are consistent with previous reports of
an association between pericyte loss and BBB break-
down in AD34 and provide further evidence that peri-
cyte loss is related to Ab level and inﬂuenced by APOE
genotype.3,4 At least within the cerebral cortex, there is
also a close relationship between PDGFRB content,
ﬁbrinogen, and blood ﬂow, in keeping with in vivo evi-
dence that loss of BBB integrity is related to pericyte
degeneration, cerebral hypoperfusion,37 and cognitive
impairment.36 Uncertainty persists as to the precise
timing of the various vascular abnormalities in AD
and the details of the complex causal interrelationships.
In Pdgfrbþ/ mice, age-related pericyte loss led to loss
of cerebral microvessels, breakdown of the BBB,
reduced cerebral blood ﬂow, and neurovascular uncou-
pling.9 Evidence that these vascular abnormalities have
the potential to exacerbate AD pathology comes from a
study in which APPsw/0 mice developed more severe Ab
and tau pathology, neuronal loss, and memory impair-
ment when they were crossed with Pdgfrbþ/ mice.33
In contrast, several lines of evidence suggest that Ab
contributes to pericyte injury,33,35,46 BBB dysfunction,3,4
and hypoperfusion.26,27,47 In recent years imaging stu-
dies, particularly in individuals with familial AD, have
shown that Ab begins to accumulate as early as 20 years
before the development of dementia, whereas cerebral
hypoperfusion occurs later, 5 to 10 years before disease
onset.11,12 In vitro studies indicate that Ab peptides
cause pericyte injury and death.33,35,46 It is also possible
that the damaging eﬀects of Ab on pericyte survival are
partly indirect, through the sequestration of PDGF-BB,
Figure 6. Reduced oxygenation in the parietal white matter in AD associated with blood–brain barrier (BBB) breakdown despite
concomitant increase in pericytes. (a) Scatterplot showing strong negative correlation between platelet-derived growth factor
receptor-b (PDGFRB) and myelin-associated glycoprotein:proteolipid protein-1 (MAG:PLP1) ratio in white matter (WM) (r¼0.31,
P¼ 0.004). (b) Scatterplot showing positive correlation between platelet-derived growth factor receptor-b (PDGFRB) level and
vascular endothelial growth factor (VEGF) level (r¼ 0.19, P¼ 0.019). (c) Scatterplot showing very strong negative correlation between
fibrinogen and MAG:PLP1 (r¼0.48, P< 0.0001). (d) Scatterplot showing very strong positive correlation between fibrinogen and
VEGF level in the white matter (r¼ 0.42, P< 0.0001). Each point in the scatterplots indicates a single AD (red circle) or control (blue
square) brain. The best-fit linear regression lines and 95% confidence intervals are superimposed.
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upregulation of VEGF, and even through competition
for binding to PDGFRB.
PDGF-BB was shown previously to be mainly asso-
ciated with Ab plaques in AD brains.48 Although we
found PDGF-BB to be increased in AD, possibly as a
physiological response to reduced tissue oxygenation,
most of it was in the insoluble fraction of the tissue,
which also contained high levels of Ab. Indeed, there
was a close correlation between the levels of PDGF-BB
and Ab within the insoluble fraction, as might be
expected if the PDGF-BB was sequestered by ﬁbrillar
Ab and thus biologically inactive – a mechanism pro-
posed to apply to another vascular trophic factor in
AD, VEGF.49 VEGF level is signiﬁcantly increased in
AD, as noted in the present study and also previously.27
Although VEGF induces vasculogenesis as well as
elongation and migration of pericytes, and may pro-
mote their interaction with capillaries during develop-
ment,50 VEGF also acts as a negative regulator of
pericyte function and maturation of vessels, interferes
with the interaction between pericytes and endothelial
cells and may promote vascular leakage.51–53 A ﬁnal
possibility to consider is whether Ab may interfere
with the binding of PDGF-BB to its pericyte receptor,
PDGFRB. Again, the VEGF signaling pathway pro-
vides an example of this mechanism, in that Ab was
shown to interfere with the binding of VEGF to
VEGF receptor-2.54
Data from previous studies suggest that there is loss
of pericytes and leakage of ﬁbrinogen at a relatively
early stage of AD.34,36,37 We found PDGFRB and
ﬁbrinogen levels to vary signiﬁcantly with Braak tangle
stage. On pairwise post hoc testing, only diﬀerences
between Braak stage 0–II and V–VI disease were signiﬁ-
cantly diﬀerent. However, our cohort included relatively
few cases in the Braak stage III–IV group and there was
greater variation between cases in this group than in the
0–II andV–VI groups. Further analysis of larger cohorts
is needed to clarify the precise timing of pericyte loss and
BBB leakage in relation to tangle pathology and other
pathological features of AD.
We found that PDGFRB level was preserved or even
increased in the white matter in AD, possibly because
there was insuﬃcient ﬁbrillar Ab to damage pericytes or
to sequester PDGF-BB. Factors other than pericyte
loss must account for the white matter hypoperfusion
and BBB leakage. Most of the perfusion of the white
matter derives from transcortical perforating arterioles,
and we reported previously that oxygenation of the
cerebral white matter declined with increasing levels
of the vasoconstrictor EDN1 in the overlying cortex,
suggesting that hypoperfusion of the white matter in
AD results partly from vasoconstriction of perforating
arterioles as they traverse the cortex.26,47,55 It is possible
that BBB leakage in the white matter is secondary to
hypoperfusion.38,39 Alternatively, it could reﬂect upre-
gulation of the plasma kallikrein-kinin system in AD,56
leading to increased production of bradykinin, which
increases the permeability of the BBB.57–59 This merits
further study.
Together, our data suggest that pericytes degenerate
in regions of brain with elevated ﬁbrillar Ab, causing or
exacerbating breakdown of the BBB, and possibly con-
tributing to loss of microvessels, hypoperfusion, and
impaired vascular clearance of Ab. Factors other than
pericyte degeneration are likely to be responsible for
hypoperfusion and breakdown of the BBB in the
white matter in AD. Further study is needed of the
timing, regional distribution, and mechanisms of peri-
cyte degeneration in AD.
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